{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-22-000071","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.498117+00:00","generated_at":"2026-06-21T23:44:52.871062+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LianBio Q3 net loss $21.9M; cash $331.8M; mavacamten Phase 3 data expected mid-2023","bullets":["Net loss of $21.9M for Q3 2022 vs $13.1M YoY; R&D expenses $8.3M, G&A $16.3M.","Cash, cash equivalents, securities $331.8M at Sep 30, 2022, down from $403.2M Dec 31, 2021; runway into 2H 2024.","Mavacamten Phase 3 EXPLORER-CN data expected mid-2023; NDA submitted in Hong Kong; included in Chinese HCM guidelines.","TP-03 Phase 3 LIBRA trial for Demodex blepharitis initiated in China; data expected Q4 2023; US NDA accepted, PDUFA Aug 25, 2023.","Phase 3 NANORAY-312 (NBTXR3) for head & neck cancer initiated in Asia; Phase 1 BBP-398 dosing begun."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-22-000071","json":"https://secwatch.observer/filing/0001831283-22-000071.json","markdown":"https://secwatch.observer/filing/0001831283-22-000071.md","text":"https://secwatch.observer/filing/0001831283-22-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000071/0001831283-22-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000071/lian-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:44:52.871062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"154be344de65d535553362d58d79d8ed433c6c76","claim":"LianBio reported third quarter ended September 30, 2022 results: net income $21.9 million.","evidence_excerpt":"LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000071/0001831283-22-000071-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"$21.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}